Hopp til innhold
NHI.no
Annonse

Influensa: Prognose

Innhold i artikkelen

Varigheten av influensasykdommen er vanligvis 1-2 uker, gjerne med høy feber den første uken. Slapphet og hoste vedvarer ofte i mer enn 2 uker. Det er ikke uvanlig at det kan gå noen uker før du er i god form etter en slik infeksjon.

Annonse

Enkelte risikogrupper, pasienter med nedsatt immunforsvar, hjerte- og lungesyke og eldre, kan få komplikasjoner i form av andre infeksjoner. Lungebetennelse er den hyppigste komplikasjonen. I slike tilfeller kan det være behov for sykehusinnleggelse.

For de aller fleste forløper en influensa ukomplisert, selv om plagene kan være betydelige i den perioden sykdommen pågår. Dersom du gjennomgår influensa, har du vanligvis god beskyttelse mot å få sykdom på ny de nærmeste årene.

Vil du vite mer

Dette dokumentet er basert på det profesjonelle dokumentet Influensa . Referanselisten for dette dokumentet vises nedenfor

  1. Gaitonde DY, Moore FC, Morgan MK. Influenza: Diagnosis and Treatment. Am Fam Physician. 2019;100(12):751-758. PubMed
  2. Smittevern & Vaksine. Fakta om influensa. Folkehelseinstituttet, sist oppdatert 18.01.2022. www.fhi.no
  3. Hayward AC, Fragaszy EB, Bermingham A, et al. Comparative community burden and severity of seasonal and pandemic influenza: results of the Flu Watch cohort study. Lancet Respiratory Medicine 2014. doi:10.1016/S2213-2600(14)70034-7 DOI
  4. Gran JM, Iversen B, Hungnes O, Aalen OO. Estimating influenza-related excess mortality and reproduction numbers for seasonal influenza in Norway, 1975-2004. Epidemiol Infect. 2010; 138:1559-1568. PMID: 20334732 PubMed
  5. Taubenberger JK, Morens DM. Influenza: the once and future pandemic. Public Health Rep. 2010;125(suppl 3):16–26. PMID: 20568566 PubMed
  6. Abdelrahman Z, Li M, Wang X. Comparative Review of SARS-CoV-2, SARS-CoV, MERS-CoV, and Influenza A Respiratory Viruses. Front Immunol. 2020;11:552909. Published 2020 Sep 11. PMID: 33013925 PubMed
  7. Peteranderl C, Herold S, Schmoldt C. Human influenza virus infections. Semin Respir Crit Care Med. 2016;37(4):487–500. PMID: 27486731 PubMed
  8. Dugas AF, Valsamakis A, Atreya MR, et al. Clinical diagnosis of influenza in the ED. Am J Emerg Med 2015 Jun; 33:770. PMID: 25827595 PubMed
  9. Jefferson T, Jones MA, Doshi P, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database of Systematic Reviews 2014, Issue 4. Art. No.: CD008965. DOI: 10.1002/14651858.CD008965.pub4 DOI
  10. Uyeki TM, Bernstein HH, Bradley JS, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. Clin Infect Dis 2018. pmid:30566567 PubMed
  11. Centers for Disease Control and Prevention. Influenza Signs and Symptoms and the Role of Laboratory Diagnostics. Last updated August 31, 2020. www.cdc.gov
  12. Butler CC, van der Velden AW, Bongard E, et al. Oseltamivir plus usual care versus usual care for influenza-like illness in primary care: an open-label, pragmatic, randomised controlled trial. Lancet. 2019. PMID: 31839279 PubMed
  13. Hanula R, Bortolussi-Courval E, Mendel A, et al. Evaluation of Oseltamivir Used to Prevent Hospitalization in Outpatients With Influenza A Systematic Review and Meta-analysis. JAMA Intern Med 2023. pmid:37306992 PubMed
  14. Zhao Y, Gao Y, Guyatt G, et al. Antivirals for post-exposure prophylaxis of influenza: a systematic review and network meta-analysis. Lancet 2024; 404: 764-772. pmid:39181596 PubMed
  15. Louie JK, Lampiris H. Treating Influenza With Neuraminidase Inhibitors: What Is the Evidence? JAMA Intern Med. 2015 Dec;175(12):1899-900. PubMed
  16. Gao Y, Guyatt G, Uyeki TM, et al. Antivirals for treatment of severe influenza: a systematic review and network meta-analysis of randomised controlled trials. Lancet 2024; 404: 753-763. pmid:39181595 PubMed
  17. Dobson J, Whitley RJ, Pocock S, et al. Oseltamivir treatment for influenza in adults: a meta-analysis of randomised controlled trials. Lancet 2015. 385;1729-37. PMID: 25640810 PubMed
  18. Heneghan CJ, Onakpoya I, Joes MA, et al. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technol Assess 2016. PMID: 27246259 PubMed
  19. Jefferson T, Jones M, Doshi P, et al. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ. 2014 9;348:g2545. doi: 10.1136/bmj.g2545. DOI
  20. Graner S, Smith T, Beau en pike-Michel C, et al. Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study. BMJ 2017. PMID: 28246106 PubMed
  21. Jefferson T, Del Mar C, Dooley L, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review. BMJ 2009; 339: b3675. PubMed
  22. Radonovich LJ Jr, Simberkoff MS, Bessesen MT, et al. N95 Respirators vs Medical Masks for Preventing Influenza Among Health Care Personnel: A Randomized Clinical Trial. JAMA. 2019 Sep 3;322(9):824-833. Pmid 31479137
  23. Folkehelseinstituttet. Vaksinasjonsveilederen. Effekt av influensavaksine. Informasjon om kunnskapsgrunnlaget. Sist oppdatert 22.06.2021. www.fhi.no
  24. Wang GF, Li W, Li K. Acute encephalopathy and encephalitis caused by influenza virus infection. Curr Opin Neurol. 2010;23(3):305-311. PMID: 20455276 PubMed
  25. Estabragh ZR, Mamas MA. The cardiovascular manifestations of influenza: a systematic review. Int J Cardiol. 2013 ;167(6):2397-403. doi: 10.1016/j.ijcard.2013.01.274. DOI
  26. European Centre for Disease Prevention and Control. Influenza virus characterisation - Summary Europe, March 2022. Published 21 Apr 2022. www.ecdc.europa.eu
  27. Paget J, Spreeuwenberg P, Charu V, et al. Global mortality associated with seasonal influenza epidemics: New burden estimates and predictors from the GLaMOR Project. J Glob Health. 2019;9(2):020421. PMID: 31673337 PubMed
Annonse
Annonse